Matthias E Liechti1, Boris B Quednow2, Evangelia Liakoni1, Dario Dornbierer2, Robin von Rotz2, Maria Salomé Gachet3, Jürg Gertsch3, Erich Seifritz2, Oliver G Bosch2. 1. Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Βasel, CH-4031, Switzerland. 2. Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Lenggstrasse 31, Zurich, CH-8032, Switzerland. 3. Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, Bern, CH-3012, Switzerland.
Abstract
AIMS: γ-Hydroxybutyrate (GHB) is used as a treatment for narcolepsy and alcohol withdrawal and as a recreational substance. Nevertheless, there are limited data on the pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of GHB in humans. We characterized the pharmacokinetic profile and exposure-psychotropic effect relationship of GHB in humans. METHODS: Two oral doses of GHB (25 and 35 mg kg(-1) ) were administered to 32 healthy male subjects (16 for each dose) using a randomized, placebo-controlled, cross-over design. RESULTS:Maximal concentrations of GHB were (geometric mean and 95% CI): 218 (176-270) nmol ml(-1) and 453 (374-549) nmol ml(-1) for the 25 and 35 mg kg(-1) GHB doses, respectively. The elimination half-lives (mean ± SD) were 36 ± 9 and 39 ± 7 min and the AUC∞ values (geometric mean and 95% CI) were 15 747 (12 854-19 290) and 40 113 (33 093-48 622) nmol∙min ml(-1) for the 20 and 35 mg kg(-1) GHB doses, respectively. Thus, plasma GHB exposure (AUC0-∞ ) rose disproportionally (+40%) with the higher dose. γ-Hydroxybutyrate produced mixed stimulant-sedative effects, with a dose-dependent increase in sedation and dizziness. It did not alter heart rate or blood pressure. A close relationship between plasma GHB exposure and its psychotropic effects was found, with higher GHB concentrations associated with higher subjective stimulation, sedation, and dizziness. No clockwise hysteresis was observed in the GHB concentration effect plot over time (i.e., no acute pharmacological tolerance). CONCLUSION: Evidence was found of a nonlinear dose-exposure relationship (i.e., no dose proportionality) at moderate doses of GHB. The effects of GHB on consciousness were closely linked to its plasma exposure and exhibited no acute tolerance.
RCT Entities:
AIMS: γ-Hydroxybutyrate (GHB) is used as a treatment for narcolepsy and alcohol withdrawal and as a recreational substance. Nevertheless, there are limited data on the pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of GHB in humans. We characterized the pharmacokinetic profile and exposure-psychotropic effect relationship of GHB in humans. METHODS: Two oral doses of GHB (25 and 35 mg kg(-1) ) were administered to 32 healthy male subjects (16 for each dose) using a randomized, placebo-controlled, cross-over design. RESULTS: Maximal concentrations of GHB were (geometric mean and 95% CI): 218 (176-270) nmol ml(-1) and 453 (374-549) nmol ml(-1) for the 25 and 35 mg kg(-1) GHB doses, respectively. The elimination half-lives (mean ± SD) were 36 ± 9 and 39 ± 7 min and the AUC∞ values (geometric mean and 95% CI) were 15 747 (12 854-19 290) and 40 113 (33 093-48 622) nmol∙min ml(-1) for the 20 and 35 mg kg(-1) GHB doses, respectively. Thus, plasma GHB exposure (AUC0-∞ ) rose disproportionally (+40%) with the higher dose. γ-Hydroxybutyrate produced mixed stimulant-sedative effects, with a dose-dependent increase in sedation and dizziness. It did not alter heart rate or blood pressure. A close relationship between plasma GHB exposure and its psychotropic effects was found, with higher GHB concentrations associated with higher subjective stimulation, sedation, and dizziness. No clockwise hysteresis was observed in the GHB concentration effect plot over time (i.e., no acute pharmacological tolerance). CONCLUSION: Evidence was found of a nonlinear dose-exposure relationship (i.e., no dose proportionality) at moderate doses of GHB. The effects of GHB on consciousness were closely linked to its plasma exposure and exhibited no acute tolerance.
Authors: Rudolf Brenneisen; Mahmoud A Elsohly; Timothy P Murphy; Joseph Passarelli; Stefan Russmann; Salvatore J Salamone; David E Watson Journal: J Anal Toxicol Date: 2004 Nov-Dec Impact factor: 3.367
Authors: S D Ferrara; S Zotti; L Tedeschi; G Frison; F Castagna; L Gallimberti; G L Gessa; P Palatini Journal: Br J Clin Pharmacol Date: 1992-09 Impact factor: 4.335
Authors: Robin von Rotz; Michael Kometer; Dario Dornbierer; Jürg Gertsch; M Salomé Gachet; Franz X Vollenweider; Erich Seifritz; Oliver G Bosch; Boris B Quednow Journal: Psychopharmacology (Berl) Date: 2017-04-20 Impact factor: 4.530
Authors: Dario A Dornbierer; Diego M Baur; Benjamin Stucky; Boris B Quednow; Thomas Kraemer; Erich Seifritz; Oliver G Bosch; Hans-Peter Landolt Journal: Neuropsychopharmacology Date: 2019-04-08 Impact factor: 7.853
Authors: Oliver G Bosch; Fabrizio Esposito; Michael M Havranek; Dario Dornbierer; Robin von Rotz; Philipp Staempfli; Boris B Quednow; Erich Seifritz Journal: Neuropsychopharmacology Date: 2017-05-31 Impact factor: 7.853
Authors: Zurina Hassan; Oliver G Bosch; Darshan Singh; Suresh Narayanan; B Vicknasingam Kasinather; Erich Seifritz; Johannes Kornhuber; Boris B Quednow; Christian P Müller Journal: Front Psychiatry Date: 2017-08-18 Impact factor: 4.157
Authors: Casper J H Wolf; Harmen Beurmanjer; Boukje A G Dijkstra; Alexander C Geerlings; Marcia Spoelder; Judith R Homberg; Arnt F A Schellekens Journal: J Clin Med Date: 2021-05-26 Impact factor: 4.241